Behavioral Rehabilitation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Market Overview

The Behavioral Rehabilitation Market is estimated to grow with a steady CAGR of 3.5 % during the forecast period from 2021-2026.

The COVID-19 pandemic is expected to have a slightly negative impact on the market. At present, countries across the globe are facing a considerable threat of COVID-19 (coronavirus). Many pharmaceutical and biotechnological companies are focusing their R&D activities on manufacturing antiseptic products and vaccines to meet the increased demand from customers. Owing to the situation, most pharmaceutical and biotechnological companies have been focusing their R&D departments on identifying new molecules or leads for the treatment of this disease.​ Many countries have already approved a vaccine for COVID-19. For instance, in December 2020, the World Health Organization (WHO) issued the emergency use validation of Pfizer/BioNTech COVID-19 mRNA vaccine globally. According to a research study by Katya Numbers et al., published in Nature Reviews Neurology in January 2021, stated that people with mental disorders like dementia are at high risk of COVID-19 infection because cognitive symptoms cause difficulty with following safeguarding procedures and living arrangements in care homes facilitate viral spread. Furthermore, older population with dementia are also more likely to have more severe disease consequences than those without dementia. <As per Lewy Body Society, stated that people with dementia and related disorders find harder to follow government guidelines designed to prevent the spread of the virus such as washing hands, maintaining the recommended physical distance, monitoring COVID-19 symptoms and staying at home. People with more severe dementia may not be able to understand or remember the guidelines due to their short-term memory loss and cognitive impairment. As per Office for National Statistics UK 2020, stated that dementia and Alzheimer’s disease were the most common pre-existing conditions found among deaths involving COVID-19 in United Kingdom.

Furthermore, due to the COVID-19 pandemic, lots of families are facing a significant economic burden, which can lead to an even greater inclination toward letting go of treatment options. Moreover, the pandemic can also have a negative impact on the new product launches, which are estimated to be the most prominent factor of the growth of the market. For instance, in April 2020, Biogen announced that it had delayed Alzheimer’s and dementia drug filing to FDA while citing the complexity of data analysis and impact on COVID-19 on its R&D resources

According to the statistics provided by the Mental Health Foundation in 2018, mental health problems were one of the primary causes of rising medical concerns. Furthermore, mental and behavioral health problems are considered to be the primary cause of disability in the age group of 20-29 years, since the past few decades. According to the same source, every year, a large number of people were diagnosed with mental illnesses in the United States. According to the United States Department of Health and Human Services (DHHS) in 2018, one in every five (20%) children and adolescents suffer from mental health disorder at some point in their life. At least, 1 in 10, or about 6 million people suffered serious emotional disturbance at some point in their life.

The treatments for behavioural disorders mainly focuses on behavioural treatment and medication. Parent management training and family therapy are considered quite effective for managing behavioural disorders. Additionally, cognitive behavioral therapy treatment is the most commonly used mechanism for managing the symptoms of behavioral disorders. However, medication treatment for these disorders is targeted toward treating underlying or co-occurring disorders, such as attention deficit hyperactivity disorder (ADHD), depression or anxiety. These developments re expected to positively affect market development.

Scope of the Report

As per the scope of the study, Behavioral health is the scientific study of the emotions, behaviors, and biology relating to a person’s mental well-being, their ability to function in everyday life, and their concept of self. Behavioral health is the preferred term for mental health.

The behavioral rehabilitation market is segmented by type of behavioral disorder (anxiety disorder, mood disorder, substance abuse disorder, personality disorder, and attention deficit disorder), by healthcare setting (outpatient behavioral rehabilitation, inpatient behavioral rehabilitation, and residential behavioral rehabilitation), by treatment method (counseling, medication, support services, other treatment methods) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Anxiety Disorder is Expected to Significant Share of the Global Behavioral Rehabilitation Market Over the Forecast Period

The anxiety disorders are different from normal feelings of anxiousness and involve excessive anxiety or fear. According to Our World in Data (OWID), an estimated 284 million people experienced an anxiety disorder in 2017, globally, making it the most prevalent mental health or neurodevelopmental disorder. Whereas, the Anxiety and Depression Association of America (ADAA) states that anxiety disorders are the most common mental illness in the United States, affecting 40 million adults of age 18 and older, i.e., 18.1% of the population each year. Even though anxiety disorders are very much treatable, only 36.9% of those suffering receive treatment, according to the Anxiety and Depression Association of America. Individuals with an anxiety disorder are three to five times more likely to visit the doctor and six times more likely to be hospitalized for psychiatric conditions than those who do not have anxiety disorders. The roots of anxiety disorders are presently unknown but probably involve a combination of factors, including genetic, psychological, environmental, and developmental.

However, many antidepressants, including escitalopram (Lexapro) and fluoxetine (Prozac), can alleviate anxiety disorders and help people lead a normal and productive life. Furthermore, increase in research and development on treatment of anxiety disorders due to overall increasing prevalence of this disorder is expected to drive the market growth over the forecast period.

To understand key trends, Download Sample Report